Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns
Trastuzumab deruxtecan (Enhertu) has demonstrated clinical efficacy in patients with HER2-low metastatic breast cancer, shifting treatment paradigms in community oncology settings. Recent real-world evidence indicates that oncologists are increasingly adopting this antibody-drug conjugate (ADC) for patients who previously lacked targeted therapy options, though clinical outcomes often mirror the findings of the landmark DESTINY-Breast04 trial.
What defines HER2-low breast cancer?
HER2-low breast cancer is defined by an immunohistochemistry (IHC) score of 1+ or an IHC score of 2+ with a negative in situ hybridization (ISH) result, according to the American Society of Clinical Oncology (ASCO). Historically, these patients were classified as HER2-negative and received standard chemotherapy. The introduction of trastuzumab deruxtecan allows for the targeted delivery of a potent cytotoxic payload directly to tumor cells expressing low levels of HER2 protein, as noted by the U.S. Food and Drug Administration (FDA).
Real-world outcomes vs. clinical trial data
In the pivotal DESTINY-Breast04 trial, patients receiving trastuzumab deruxtecan experienced a median progression-free survival (PFS) of 10.1 months, compared to 5.4 months for those receiving physician’s choice of chemotherapy. Recent observational studies in community oncology settings suggest that real-world PFS often aligns with these clinical trial benchmarks. However, community practitioners report higher rates of dose modifications and treatment interruptions due to adverse events, such as interstitial lung disease (ILD) and neutropenia, compared to the controlled environment of Phase III trials.
How do treatment patterns vary in community settings?
Treatment patterns in community clinics reveal a transition toward earlier integration of trastuzumab deruxtecan in the metastatic setting. According to data published in Oncology Times, oncologists are prioritizing the identification of HER2-low status through reflex testing at the time of metastatic diagnosis. This shift contrasts with earlier practice, where HER2 status was often only confirmed as positive or negative, potentially missing candidates for ADC therapy.
Comparison of Trial vs. Real-World Factors
| Factor | DESTINY-Breast04 Trial | Community Oncology Setting |
|---|---|---|
| Patient Selection | Strict eligibility criteria | Broad, including comorbidities |
| Dose Management | Protocol-driven | Individualized, frequent adjustments |
| Efficacy (PFS) | 10.1 months (median) | Generally consistent with trial |
What should patients monitor during treatment?
Patients undergoing treatment with trastuzumab deruxtecan require close monitoring for pulmonary symptoms. The National Comprehensive Cancer Network (NCCN) guidelines emphasize that interstitial lung disease (ILD) remains a significant safety concern. Clinicians are advised to assess patients for new or worsening cough, dyspnea, or fever at every visit. Early detection and prompt management, often involving corticosteroids or treatment cessation, remain the standard of care to mitigate long-term pulmonary complications.
Future directions for HER2-low therapy
The success of trastuzumab deruxtecan has prompted ongoing research into its use in earlier stages of breast cancer. Clinical trials are currently evaluating the drug’s performance in the neoadjuvant and adjuvant settings to determine if its efficacy can prevent recurrence in high-risk patients. As data matures, the medical community expects to refine the biomarkers used to predict response beyond simple IHC scoring, potentially incorporating quantitative HER2 expression levels to further personalize treatment.